This content is machine translated Renal insufficiency in general practice Improve early detection and inhibit progression The most common causes of chronic kidney disease (CKD) include diabetes and hypertension. Regular screening is recommended if there is an increased risk of CKD. In addition to the eGFR,…
View Post 10 min This content is machine translated Diabetic foot syndrome Exercise and DFS – does every step make you fit? Regular physical activity and increasing physical activity are part of the basic therapy for the treatment of type 2 diabetes in national and international guidelines. With structured aerobic exercise training,… CME-Test
View Post 9 min This content is machine translated Update ESC Guidelines 2023 Detailed recommendations for cardiovascular diseases in diabetes The updated guideline recommends important innovations in the areas of screening, cardiovascular risk assessment in diabetes mellitus and aspects of evidence-based cardiovascular risk reduction in type 2 diabetes patients with…
View Post 3 min This content is machine translated Type 2 diabetes: PIONEER REAL Switzerland study Semaglutide in oral form convinces in everyday practice In the non-interventional PIONEER REAL Switzerland study, adult type 2 diabetics treated with oral semaglutide as part of routine clinical care achieved clinically significant improvement in glycemic control with no…
View Post 3 min This content is machine translated Myasthenia gravis Something is happening in the treatment management of autoimmune diseases Myasthenia gravis (or myasthenia for short) is a rare disease in which the immune system turns against its own body. Autoantibodies disrupt the transmission of impulses at the interface between…
View Post 10 min This content is machine translated GLP-1 agonists continue to gain ground Semaglutide in patients with obesity and heart failure It has long been known that the active ingredient class of glucagon-like peptide-1 agonists (GLP-1) reduces cardiovascular consequences in diabetics and leads to significant weight loss in patients with obesity.…
View Post 4 min This content is machine translated SGLT-2-i in type 2 diabetes and CVD Cardioprotective mechanisms of action of empagliflozin – what’s new? Empagliflozin is known to reduce the risk of atherosclerotic cardiovascular disease (CVD) in people with type 2 diabetes and high cardiovascular risk. The mechanisms underlying these effects are not yet…
View Post 4 min This content is machine translated AID systems for type 1 diabetes New real-world data shows: AI makes the difference In hybrid closed-loop systems, algorithms control the automated insulin delivery (AID). Compared to conventional insulin administration, this not only has a favorable effect on HbA1c values, but also on patient-oriented…
View Post 4 min This content is machine translated Dual GIP/GLP-1 RA in type 2 diabetes Tirzepatide proves multiple benefits In the Phase III SURPASS study program, the dual receptor agonist tirzepatide performed convincingly. The results of several post-hoc analyses are now also available. At the annual meeting of the…
View Post 6 min This content is machine translated Coronary heart disease and type 2 diabetes Relationship between baseline FFA values and all-cause mortality. It is known that elevated levels of free fatty acids (FFA) are strongly associated with all-cause mortality in patients with coronary heart disease (CHD) and the development of type 2…
View Post 3 min This content is machine translated Polyneuropathies Disorders of brain, spinal cord and nerve function Polyneuropathies are generalized diseases of the peripheral nervous system. With a prevalence of 5-8%, patients with chronic alcohol abuse, diabetes or malignant diseases are most affected. In addition to treatment…
